

**SOUTH DAKOTA MEDICAID  
PRIOR AUTHORIZATION CRITERIA**

*Physician Administered Drugs, Vaccines, and Immunizations*

**Palivizumab (Synagis)– PA Criteria**

HCPC: 90378

Synagis is an immune therapy against Respiratory Syncytial Virus (RSV) indicated for prevention of RSV in infants under 24 months of age. It is only covered from November 1st of each calendar year through March 31st of the following calendar year though coverage outside this time will be considered if determined medically necessary by the South Dakota Medicaid Medical Director. Synagis is covered by South Dakota Medicaid following prior authorization when the patient meets the following criteria:

- **Initial Therapy (must meet all):**
  - The medication has been recommended by a neonatologist, pediatric pulmonologist, or pediatric cardiologist
  - Child has not received Beyfortus (nirsevimab) in the same season
  - The child meets **one** of the following categories listed below:
    - Children under 1 year of age at the onset of RSV season who were 28 & 0/7 weeks or less gestational age at birth
    - Children under 6 months of age at the onset of the RSV season who were born between 28 & 1/7 and 32 & 0/7 weeks gestational age at birth
    - Children under 3 months of age at the onset of the RSV season or who are born during the RSV season (11/1-3/31) who were between 32 & 1/7 and 35 & 0/7 weeks gestational age at birth with one of these 2 risk factors: day care attendance or a sibling in the household less than 5 years of age
    - Children under 2 years of age at the onset of the RSV season with evidence of ongoing lung disease such as bronchopulmonary dysplasia or cystic fibrosis requiring treatment with oral bronchodilators, supplemental oxygen, diuretics, or nebulized or inhaled medications to stabilize the disease in the last 6 months
    - Children under 2 years of age at the onset of the RSV season with evidence of hemodynamically significant cyanotic or acyanotic congenital heart disease and 1 of the following: receiving medication to control congestive heart failure, moderate to severe pulmonary hypertension, or undergoing surgical procedures that use cardiopulmonary bypass
    - Children under 2 years of age at the onset of the RSV season with immunodeficiencies that may make them more susceptible to severe lower respiratory tract disease related to RSV
    - Any child under 2 years of age at the onset of the RSV season felt to be at high risk for significant lower respiratory tract illness related to RSV
  - Approval duration: 5 months (or through March 31 of calendar year, whichever is sooner)
- **Continuation of Therapy: not authorized**